Van Eck M, De Winther M P, Herijgers N, Havekes L M, Hofker M H, Groot P H, Van Berkel T J
Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University Medical Center, Sylvius Laboratories, Leiden University (The Netherlands).
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2600-6. doi: 10.1161/01.atv.20.12.2600.
In the arterial wall, scavenger receptor class A (SRA) is implicated in pathological lipid deposition. In contrast, in the liver, SRA is suggested to remove modified lipoproteins from the circulation, thereby protecting the body from their pathological action. The role of SRA on bone marrow-derived cells in lipid metabolism and atherogenesis was assessed in vivo by transplantation of bone marrow cells overexpressing human SRA (MSR1) to apoE-deficient mice. In vitro studies with peritoneal macrophages from the transplanted mice showed that macrophage scavenger receptor function, as measured by cell association and degradation studies with acetylated LDL, was approximately 3-fold increased on overexpression of MSR1 in bone marrow-derived cells as compared with control mice. Despite the increased macrophage scavenger receptor function in vitro, no significant effect of MSR1 overexpression in bone marrow-derived cells on the in vivo atherosclerotic lesion development was found. In addition to arterial wall macrophages, liver sinusoidal Kupffer cells also overexpress MSR1 after bone marrow transplantation, which may scavenge atherogenic particles more efficiently from the blood compartment. Introduction of bone marrow cells overexpressing human MSR1 in apoE-deficient mice induced a significant reduction in serum cholesterol levels of approximately 20% (P:<0.001, 2-way ANOVA) as the result of a decrease in VLDL cholesterol. It is suggested that the reduction in VLDL cholesterol levels is due to increased clearance of modified lipoproteins by the overexpressed MSR1 in Kupffer cells of the liver, thereby protecting the arterial wall against the proatherogenic action of modified lipoproteins.
在动脉壁中,A类清道夫受体(SRA)与病理性脂质沉积有关。相比之下,在肝脏中,SRA被认为可从循环中清除修饰的脂蛋白,从而保护身体免受其病理作用的影响。通过将过表达人SRA(MSR1)的骨髓细胞移植到载脂蛋白E缺陷小鼠体内,在体内评估了SRA对骨髓来源细胞在脂质代谢和动脉粥样硬化发生中的作用。对移植小鼠腹腔巨噬细胞的体外研究表明,与对照小鼠相比,骨髓来源细胞中MSR1过表达时,通过乙酰化低密度脂蛋白的细胞结合和降解研究测定的巨噬细胞清道夫受体功能增加了约3倍。尽管体外巨噬细胞清道夫受体功能增强,但未发现骨髓来源细胞中MSR1过表达对体内动脉粥样硬化病变发展有显著影响。除了动脉壁巨噬细胞外,肝窦状隙枯否细胞在骨髓移植后也过表达MSR1,这可能更有效地从血液中清除致动脉粥样硬化颗粒。在载脂蛋白E缺陷小鼠中引入过表达人MSR1的骨髓细胞,由于极低密度脂蛋白胆固醇降低,导致血清胆固醇水平显著降低约20%(P<0.001,双向方差分析)。提示极低密度脂蛋白胆固醇水平降低是由于肝脏枯否细胞中过表达的MSR1增加了对修饰脂蛋白的清除,从而保护动脉壁免受修饰脂蛋白的促动脉粥样硬化作用。